Published in Antimicrob Agents Chemother on June 01, 2001
Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats. Antimicrob Agents Chemother (2005) 1.13
Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. Br J Pharmacol (2004) 0.90
Lack of effect of experimental hypovolemia on imipenem muscle distribution in rats assessed by microdialysis. Antimicrob Agents Chemother (2005) 0.88
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats. Antimicrob Agents Chemother (2003) 0.86
Pharmacokinetic-pharmacodynamic modeling of electroencephalogram effect of imipenem in rats with acute renal failure. Antimicrob Agents Chemother (2001) 0.85
Norfloxacin-induced electroencephalogram alteration and seizures in rats are not triggered by enhanced levels of intracerebral glutamate. Antimicrob Agents Chemother (2003) 0.75
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther (1979) 5.13
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther (1994) 2.39
Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. Am J Med (1985) 1.44
Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med (1988) 1.41
Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1996) 1.38
Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother (1990) 1.24
Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother (1991) 1.19
Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother (1995) 1.16
Antibiotic-induced convulsions. Crit Care Clin (1997) 1.15
Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J (1991) 1.14
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. J Pharmacol Exp Ther (1998) 1.11
Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of pefloxacin and norfloxacin in rats. J Pharmacol Exp Ther (1997) 1.09
Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis. J Antimicrob Chemother (1985) 1.08
Animal model for evaluating the convulsive liability of beta-lactam antibiotics. Antimicrob Agents Chemother (1988) 1.03
The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother (1986) 1.00
Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats. Antimicrob Agents Chemother (1999) 0.99
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther (1998) 0.99
Seizure activity associated with imipenem use: clinical case reports and review of the literature. DICP (1991) 0.92
Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother (1989) 0.91
Seizure-like activity associated with imipenem-cilastatin. Drug Intell Clin Pharm (1987) 0.90
Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats. Pharm Res (1998) 0.89
Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylenetetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions. J Pharmacol Exp Ther (1985) 0.89
Kinetics of drug action in disease states. XVI. Pharmacodynamics of theophylline-induced seizures in rats. J Pharmacol Exp Ther (1986) 0.89
Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol (1991) 0.89
Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther (1984) 0.89
Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot (Tokyo) (1995) 0.88
Effects of some excitatory amino acid antagonists and drugs enhancing gamma-aminobutyric acid neurotransmission on pefloxacin-induced seizures in DBA/2 mice. Antimicrob Agents Chemother (1997) 0.87
Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections. Antimicrob Agents Chemother (1986) 0.87
Effects of some quinolones on imipenem-induced seizures in DBA/2 mice. Gen Pharmacol (1994) 0.86
Neurotoxicity of carbapenem antibacterials. Drug Saf (1996) 0.86
Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice. J Pharm Pharmacol (1995) 0.84
The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide. Br J Clin Pharmacol (1998) 0.84
Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats. Pharm Res (1999) 0.84
Imipenem but not meropenem induces convulsions in DBA/2 mice, unrelated to cerebrospinal fluid concentrations. Fundam Clin Pharmacol (2000) 0.84
Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. Br J Pharmacol (2000) 0.80
Comparative cerebrospinal fluid diffusion of imipenem and meropenem in rats. J Pharm Pharmacol (2000) 0.79
Determination of imipenem in human plasma, urine and tissue by high-performance liquid chromatography. J Pharm Biomed Anal (1990) 0.79
Imipenem-cilastatin: the promise of single-agent antimicrobial therapy fulfilled? Clin Pharm (1986) 0.77
Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett (1995) 0.77
Predictive factors of long-term compliance with nasal continuous positive airway pressure treatment in sleep apnea syndrome. Chest (1994) 1.15
Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther (2007) 1.09
Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of pefloxacin and norfloxacin in rats. J Pharmacol Exp Ther (1997) 1.09
Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis (2013) 1.08
Chrononephrotoxicity in rat of a vancomycin and gentamicin combination. Pharmacol Toxicol (1992) 1.06
In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci (2000) 1.01
Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats. Antimicrob Agents Chemother (1999) 0.99
Psychological health in central hypersomnias: the French Harmony study. J Neurol Neurosurg Psychiatry (2009) 0.97
Influence of correction of flow limitation on continuous positive airway pressure efficiency in sleep apnoea/hypopnoea syndrome. Eur Respir J (1998) 0.97
Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination. Lab Anim (2000) 0.95
Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med (2003) 0.95
Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res (1999) 0.94
Colistin in critically ill patients. Minerva Anestesiol (2012) 0.93
Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis. Eur J Clin Pharmacol (1989) 0.90
Circadian variations in the renal toxicity of gentamicin in rats. Toxicol Lett (1988) 0.90
A new approach for early assessment of the epileptogenic potential of quinolones. Antimicrob Agents Chemother (1998) 0.89
Effects of inhaled salbutamol in exercising non-asthmatic athletes. Thorax (2001) 0.89
Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats. Pharm Res (1998) 0.89
Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int J Pharm (2011) 0.89
Plethysmography for the assessment of pneumococcal pneumonia and passive immunotherapy in a mouse model. Eur Respir J (2001) 0.89
Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Ren Fail (1997) 0.88
Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. Pharm Res (2000) 0.88
In vitro comparative studies of two marketed transdermal nicotine delivery systems: Nicopatch and Nicorette. Int J Pharm (2003) 0.87
[Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg]. Pathol Biol (Paris) (1986) 0.87
Habitual snoring as a risk factor for brain infarction. Acta Neurol Scand (1995) 0.87
Pharmacokinetic-pharmacodynamic modeling of electroencephalogram effect of imipenem in rats with acute renal failure. Antimicrob Agents Chemother (2001) 0.85
Long-term evolution of daytime somnolence in patients with sleep apnea/hypopnea syndrome treated by continuous positive airway pressure. Sleep (1997) 0.85
Imipenem but not meropenem induces convulsions in DBA/2 mice, unrelated to cerebrospinal fluid concentrations. Fundam Clin Pharmacol (2000) 0.84
Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats. Pharm Res (1999) 0.84
Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med (1991) 0.83
[The sleep apnea syndrome: diagnosis and management in general practice. A descriptive survey of 579 French general practitioners]. Rev Mal Respir (2002) 0.83
Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. Eur J Clin Pharmacol (1987) 0.81
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res (1995) 0.81
Relationship between sleep apnoea syndrome, snoring and headaches. Cephalalgia (2002) 0.81
Convulsant and subconvulsant doses of norfloxacin in the presence and absence of biphenylacetic acid alter extracellular hippocampal glutamate but not gamma-aminobutyric acid levels in conscious rats. Antimicrob Agents Chemother (2002) 0.81
[Evaluation of trypan blue toxicity in idiopathic epiretinal membrane surgery with macular function test using multifocal electroretinography: seven prospective case studies]. J Fr Ophtalmol (2005) 0.81
Footshock stress but not contextual fear conditioning induces long-term enhancement of auditory-evoked potentials in the basolateral amygdala of the freely behaving rat. Eur J Neurosci (1998) 0.80
Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia. J Antimicrob Chemother (2004) 0.80
[Cigarette smoking and sleep disturbance]. Rev Mal Respir (2006) 0.80
Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. Br J Pharmacol (2000) 0.80
Brain microdialysis distribution study of cefotaxime in a patient with traumatic brain injury. Br J Anaesth (2012) 0.80
Comparative cerebrospinal fluid diffusion of imipenem and meropenem in rats. J Pharm Pharmacol (2000) 0.79
Saturable rate of cefatrizine absorption after oral administration to humans. J Pharmacokinet Biopharm (1990) 0.79
Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. Clin Pharmacol Ther (2010) 0.79
A survey on the use of gentamicin in infective endocarditis. Eur J Clin Microbiol Infect Dis (2011) 0.79
In situ nasal absorption of midazolam in rats. Int J Pharm (2001) 0.77
Chlorophacinone intoxication. A biological and toxicological study. J Toxicol Clin Toxicol (1989) 0.76
Subcutaneous octreotide for the prevention of early variceal rebleeding. Hepatology (1996) 0.76
Debrisoquine and dextromethorphan phenotyping and antidepressant treatment. Therapie (1991) 0.76
[Cytochrome p450 IID6, its role in psychopharmacology]. Ann Med Psychol (Paris) (1995) 0.76
A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin. Eur J Pharm Sci (2012) 0.76
Effects of electrolytic lesions of the superior olivary complex and trapezoid body on brainstem auditory-evoked potentials in the guinea pig. I. Vertex-tragus recordings. Audiology (1988) 0.76
Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med (1994) 0.76
[Comparative study of the tissue distribution of two beta-mimetics: clenbuterol and salbutamol in the dog]. J Pharmacol (1987) 0.76
Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Pharmazie (2012) 0.76
Decreased erythrocyte penetration of pefloxacin in cirrhotic patients. J Antimicrob Chemother (1987) 0.76
Diffusion of ofloxacin in human tissues. Chemioterapia (1987) 0.75
A comparative study of enzymuria, in the rat, of the drug combinations amikacin/vancomycin and amikacin/teicoplanin. Ren Fail (1993) 0.75
Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers. Br J Clin Pharmacol (1990) 0.75
Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. Lab Anim (1996) 0.75
[Contrast agents in magnetic resonance imaging]. J Radiol (1985) 0.75
[Cortisol and 11-desoxycortisol determination in blood by high performance liquid chromatography]. Ann Biol Clin (Paris) (1981) 0.75
Atrial arrhythmia as a complication of nasal CPAP. Chest (1992) 0.75
[Tissue distribution of 3 beta-blockers in dogs]. Ann Pharm Fr (1987) 0.75
[Demonstration of seasonal variations of circadian rhythm in gentamicin-induced chrono-nephrotoxicity in rats]. Pathol Biol (Paris) (1988) 0.75
[Comparative study by computerized EEG of dementia of the ALzheimer type and Parkinson's disease with dementia]. Neurophysiol Clin (1992) 0.75
[Comparative pharmacokinetics of piperacillin in young and elderly subjects]. Presse Med (1986) 0.75
[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. Ann Fr Anesth Reanim (1995) 0.75
Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man. Fundam Clin Pharmacol (1994) 0.75
Effect of tamoxifen on the pharmacokinetics of theophylline in rats. J Pharm Pharmacol (1997) 0.75
A study of the interaction of viloxazine with theophylline. Ther Drug Monit (1989) 0.75
Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin. Therapie (1997) 0.75
Minor and clinically non-significant interaction between toloxatone and amitriptyline. Eur J Clin Pharmacol (1993) 0.75
Same location of the source of P1 of BAEPs and N1 of CAP in guinea pig. Hear Res (1991) 0.75
[Pharmacokinetics of steady-state sotalol in the elderly]. Therapie (1988) 0.75
Three-dimensional curves: main parameters of brainstem auditory-evoked responses in the normal subject. Audiology (1986) 0.75
[Pharmacokinetic bases of bioavailability studies]. Therapie (1988) 0.75
Supersonic-jet experiments using a high-energy laser. Phys Rev Lett (2007) 0.75
[Specific and non-specific contrast media for MRI of tumors. Experimental study of human breast carcinoma]. J Radiol (1989) 0.75
[Characteristics of 3-dimensional representations of brain stem auditory evoked potentials]. Rev Electroencephalogr Neurophysiol Clin (1986) 0.75
Fluoxetine and norfluoxetine plasma levels after treatment discontinuation in man. Therapie (1995) 0.75
[Crossover pharmacokinetic study of quinupramine in 6 subjects]. Encephale (1982) 0.75
A pharmacokinetic/pharmacodynamic approach to show that not all fluoroquinolones exhibit similar sensitivity toward the proconvulsant effect of biphenyl acetic acid in rats. J Antimicrob Chemother (2001) 0.75
[Differences in efficiency of continuous positive pressure respiration on the diurnal somnolence of patients with sleep apnea/hypoapnea syndrome]. Rev Mal Respir (1995) 0.75
Metabolic interaction between tricyclic antidepressant and fluvoxamine and fluoxetine, a pharmacogenetic approach. Clin Neuropharmacol (1992) 0.75
Microcomputer analysis of three-channel Lissajous' trajectory of auditory brainstem evoked potentials. Comput Methods Programs Biomed (1990) 0.75
[Physiologic compatibility of compartment models used in pharmacokinetics]. Therapie (1987) 0.75